Search Results - "AOYAMA, YUMI"

Refine Results
  1. 1

    Immune reconstitution inflammatory syndrome in non‐HIV immunosuppressed patients by Sueki, Hirohiko, Mizukawa, Yoshiko, Aoyama, Yumi

    Published in Journal of dermatology (01-01-2018)
    “…Immune reconstitution inflammatory syndrome (IRIS) represents a clinical phenomenon of immune‐mediated inflammation against various antigens, including…”
    Get full text
    Journal Article
  2. 2
  3. 3

    Role of pro‐inflammatory cytokines in the pathophysiology of herpes simplex virus superinfection in Darier’s disease by Yamamoto, Takenobu, Aoyama, Yumi

    Published in Journal of dermatology (01-10-2021)
    “…Darier’s disease (DD) and Hailey–Hailey disease (HHD), belonging to a hereditary acantholytic dermatosis caused by mutations in ATP2A2 and ATP2C1,…”
    Get full text
    Journal Article
  4. 4

    Risk of Progression to Autoimmune Disease in Severe Drug Eruption: Risk Factors and the Factor-Guided Stratification by Mizukawa, Yoshiko, Aoyama, Yumi, Takahashi, Hayato, Takahashi, Ryo, Shiohara, Tetsuo

    Published in Journal of investigative dermatology (01-03-2022)
    “…The identification of risk factors is key not only to uncover the pathogenesis of autoimmune disease but also to predict progression to autoimmune disease…”
    Get full text
    Journal Article
  5. 5

    Detection of multinucleated giant cells in differentiated keratinocytes with herpes simplex virus and varicella zoster virus infections by modified Tzanck smear method by Yamamoto, Takenobu, Aoyama, Yumi

    Published in Journal of dermatology (01-01-2021)
    “…Herpes simplex virus (HSV) and varicella zoster virus (VZV) infections induce the formation of intraepidermal vesicles containing acantholytic cells and…”
    Get full text
    Journal Article
  6. 6

    SARS‐CoV‐2 vaccine‐triggered conversion from systemic lupus erythematosus (SLE) to bullous SLE and dipeptidyl peptidase 4 inhibitors‐associated bullous pemphigoid by Nakahara, Yukiko, Yamane, Mariko, Sunada, Midori, Aoyama, Yumi

    Published in Journal of dermatology (01-02-2023)
    “…Bullous systemic lupus erythematosus (BSLE) is a rare blistering disease in patients with SLE. BSLE is a heterogenous disease caused by autoantibodies to the…”
    Get full text
    Journal Article
  7. 7

    Clinical features of dipeptidyl peptidase‐4 inhibitor‐associated bullous pemphigoid in Japan: A nationwide retrospective observational study by Sugiyama, Seiko, Yamamoto, Takenobu, Aoyama, Yumi

    Published in Journal of dermatology (01-07-2022)
    “…Many cases of bullous pemphigoid (BP) have been reported in patients taking dipeptidyl peptidase‐4 inhibitors (DPP‐4i), which are the most widely used…”
    Get full text
    Journal Article
  8. 8
  9. 9

    Herpes simplex virus-induced murine dry skin model through sweating disturbance by Asanuma, Yumiko, Ishimaru, Hironobu, Sato, Tetsuko, Yamamoto, Takenobu, Aoyama, Yumi

    Published in Journal of dermatological science (01-09-2022)
    “…Given that ocular glands become infected secondarily to herpes simplex virus 1 (HSV-1) keratitis, resulting in the loss of tear production, sweat glands may…”
    Get full text
    Journal Article
  10. 10

    Systemic capillary leak syndrome triggered by anti‐programmed death 1 checkpoint inhibitor in psoriasis by Umeda, Yoshiyasu, Hayashi, Hiroaki, Sugiyama, Seiko, Aoyama, Yumi

    Published in Journal of dermatology (01-11-2020)
    “…Programmed death 1 (PD‐1) inhibitors are increasingly used for the treatment of malignancies. Despite the clinical benefits, unpredictable and potentially…”
    Get full text
    Journal Article
  11. 11

    Cell-to-cell transmission of HSV-1 in differentiated keratinocytes promotes multinucleated giant cell formation by Yamamoto, Yoshiko, Yamamoto, Takenobu, Aoyama, Yumi, Fujimoto, Wataru

    Published in Journal of dermatological science (01-01-2019)
    “…•Differentiated keratinocytes can form multinucleated giant cell with HSV-1 infection.•HSV-1 infected differentiated keratinocytes can disrupt the adjacent…”
    Get full text
    Journal Article
  12. 12

    Cathelicidin Antimicrobial Peptide LL-37 in Psoriasis Enables Keratinocyte Reactivity against TLR9 Ligands by Morizane, Shin, Yamasaki, Kenshi, Mühleisen, Beda, Kotol, Paul F., Murakami, Masamoto, Aoyama, Yumi, Iwatsuki, Keiji, Hata, Tissa, Gallo, Richard L.

    Published in Journal of investigative dermatology (01-01-2012)
    “…Here we show that keratinocytes in psoriatic lesional skin express increased Toll-like receptor (TLR) 9 that similarly localizes with elevated expression of…”
    Get full text
    Journal Article
  13. 13

    Anti-Cytomegalovirus Therapy: Whether and When to Initiate, Those Are the Questions by Aoyama, Yumi, Sugiyama, Seiko, Yamamoto, Takenobu

    Published in Pharmaceuticals (Basel, Switzerland) (27-06-2022)
    “…Cytomegalovirus (CMV) reactivation in patients with autoimmune bullous disease (AIBD) or severe drug eruption treated with immunosuppressive therapy was…”
    Get full text
    Journal Article
  14. 14

    Sweat is a most efficient natural moisturizer providing protective immunity at points of allergen entry by Shiohara, Tetsuo, Mizukawa, Yoshiko, Shimoda-Komatsu, Yurie, Aoyama, Yumi

    Published in Allergology International (01-10-2018)
    “…Although there is a growing acceptance that sweat could play a detrimental role in various allergic skin diseases, the possibility that sweat is also involved…”
    Get full text
    Journal Article
  15. 15

    A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral Bruton’s tyrosine kinase inhibitor, in pemphigus by Yamagami, Jun, Ujiie, Hideyuki, Aoyama, Yumi, Ishii, Norito, Tateishi, Chiharu, Ishiko, Akira, Ichijima, Tomoki, Hagihara, Shunsuke, Hashimoto, Koji, Amagai, Masayuki

    Published in Journal of dermatological science (01-09-2021)
    “…•Tirabrutinib, an oral BTK inhibitor, was evaluated in patients with pemphigus.•The complete remission rate with tirabrutinib after 24-week treatment was 18.8…”
    Get full text
    Journal Article
  16. 16

    Biomarkers for predicting immune reconstitution inflammatory syndrome in dipeptidyl peptidase‐4 inhibitor‐associated bullous pemphigoid: A retrospective observational study with a case series by Sugiyama, Seiko, Yamamoto, Takenobu, Aoyama, Yumi

    Published in JEADV clinical practice (01-03-2024)
    “…Background The prognosis of dipeptidyl peptidase‐4 inhibitor‐associated bullous pemphigoid (DPP‐4i‐BP) is variable, with some cases showing spontaneous…”
    Get full text
    Journal Article
  17. 17

    Japanese guidelines for the management of pemphigus by Amagai, Masayuki, Tanikawa, Akiko, Shimizu, Tomoko, Hashimoto, Takashi, Ikeda, Shigaku, Kurosawa, Michiko, Niizeki, Hironori, Aoyama, Yumi, Iwatsuki, Keiji, Kitajima, Yasuo

    Published in Journal of dermatology (01-06-2014)
    “…The Committee for Guidelines for the Management of Pemphigus was organized as one element of the Japanese Dermatological Association (JDA) and the Ministry of…”
    Get full text
    Journal Article
  18. 18
  19. 19
  20. 20